Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.
Markman
Maurie
M
University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. mmarkman@mdanderson.org
D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D023381:Endpoint Determination; D006801:Humans; D009369:Neoplasms / Q000401:mortality*; D012107:Research Design